Bausch + Lomb (NYSE:BLCO) Posts Quarterly Earnings Results

Bausch + Lomb (NYSE:BLCO) posted its earnings results on Wednesday. The company reported $0.25 EPS for the quarter, topping analysts’ consensus estimates of $0.23 by $0.02, Zacks reports. The business had revenue of $1.28 billion for the quarter, compared to analysts’ expectations of $1.26 billion. Bausch + Lomb had a positive return on equity of 3.17% and a negative net margin of 7.86%. The business’s revenue was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.24 earnings per share. Bausch + Lomb updated its FY 2025 guidance to EPS.

Bausch + Lomb Stock Performance

NYSE BLCO opened at $16.29 on Thursday. The company has a current ratio of 1.57, a quick ratio of 0.95 and a debt-to-equity ratio of 0.69. The business’s 50 day moving average is $17.47 and its two-hundred day moving average is $18.15. The stock has a market capitalization of $5.74 billion, a price-to-earnings ratio of -15.51, a PEG ratio of 2.17 and a beta of 0.46. Bausch + Lomb has a 12-month low of $13.16 and a 12-month high of $21.69.

Wall Street Analyst Weigh In

BLCO has been the topic of several research analyst reports. Citigroup lowered Bausch + Lomb from a “buy” rating to a “neutral” rating and cut their price target for the stock from $24.00 to $22.00 in a research report on Wednesday, December 11th. Royal Bank of Canada reduced their price target on shares of Bausch + Lomb from $23.00 to $22.00 and set an “outperform” rating for the company in a research report on Wednesday, January 29th. Wells Fargo & Company decreased their price target on shares of Bausch + Lomb from $26.00 to $24.00 and set an “overweight” rating for the company in a research note on Thursday, January 16th. Needham & Company LLC reaffirmed a “hold” rating on shares of Bausch + Lomb in a report on Thursday, October 31st. Finally, HC Wainwright reiterated a “buy” rating and set a $23.00 target price on shares of Bausch + Lomb in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, Bausch + Lomb currently has a consensus rating of “Hold” and a consensus target price of $20.25.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.